Impact of a pharmacist-led diabetes management on outcomes, utilization, and cost

• DOI: 10.2147/ceor.s174595
• Publication Date: 2018-09-23T23:30:36Z
• Authors: Daniel D Maeng; Jove Graham; Michael Bogart; Jing Hao; Eric A Wright
• Keywords: Disease management

Purpose: Pharmacist-led medication therapy disease management (MTDM) has shown improvement in clinical outcomes patients with certain chronic diseases. However, only limited data demonstrating the impact on health care utilization and cost of are available. This study seeks to evaluate a pharmacist-led MTDM program surrogate outcomes, utilization, among diabetes mellitus. Methods: A retrospective cohort was conducted by utilizing electronic records insurance claims data. Patients were identified between February 2011 December 2014. Data collected from Geisinger, large integrated system located Pennsylvania southern New Jersey. total 5,500 mellitus identified; 2,750 enrolled 1-to-1 propensity score-matched comparison not program. Results: There no differences groups composite HbA1c, blood pressure, or low-density lipoprotein cholesterol goal attainment at 12 months (12% vs 12%, P =0.53). HbA1c reached more frequently without compared those (57% 51%, <0.0001). significant two cohorts pressure goals months. associated reduced all-cause hospitalization rate (–19.6%; =0.02) as well increased primary physician visits (18.5%; <0.001) lower average per-member-per-month medical (–13%, =0.027). Conclusion: Despite lack fewer hospitalizations, possibly facilitated monitoring (ie, higher utilization). Keywords: diabetes, pharmacist, management,